| 1 |
Hung-Chang Chien |
Zte |
11 |
| 2 |
George Blandino |
AT&T |
9 |
| 3 |
Sampath Rangarajan |
Nec Laboratories America |
8 |
| #4 |
Rohit Vijay |
ExxonMobil |
6 |
| #5 |
Jane C. Cheng |
ExxonMobil |
5 |
| #5 |
Wen-Jui Li |
AT&T |
5 |
| #5 |
Darshan Parikh |
Bristol-Myers Squibb |
5 |
| #5 |
Satish Pulapura |
Tyrx |
5 |
| #5 |
Bharat Kumar |
IBM |
5 |
| #5 |
Christine N. Elia |
ExxonMobil |
5 |
| #5 |
Hui Cheng |
Sri International |
5 |
| #12 |
Zhigang Hao |
Colgate-Palmolive |
4 |
| #12 |
Douglas M. Pasko |
Verizon |
4 |
| #14 |
Kun Wang |
ExxonMobil |
3 |
| #14 |
Paul Gausman |
AT&T |
3 |
| #14 |
Ashraf W. Lotfi |
Enpirion |
3 |
| #14 |
William Strohl |
Merck |
3 |
| #14 |
Anil Menon |
Signal Pharmaceuticals |
3 |
| #14 |
Dawn E. Smith |
Temptime |
3 |
| #14 |
David C. Calabro |
ExxonMobil |
3 |
| #21 |
Jacques Mauger |
Aventis Pharma S.A. |
2 |
| #21 |
Prasad Golla |
Alcatel |
2 |
| #21 |
Emmett M. Partain, III |
Rohm And Haas |
2 |
| #21 |
Gilles Bignan |
Johnson & Johnson |
2 |
| #21 |
Rene Belder |
Ligand Pharmaceuticals Incorporated |
2 |
| #21 |
Konstantin Konstantinov |
Genzyme |
2 |
| #21 |
Veena Warikoo |
Genzyme |
2 |
| #21 |
Xintian Ming |
Johnson & Johnson |
2 |
| #21 |
Scott Kachlany |
Rutgers, The State University Of New Jersey |
2 |
| #21 |
Sidharth R. Sibal |
Verizon |
2 |
| #21 |
Jay A. Tischfield |
Unknown |
2 |
| #21 |
Xiaolei Gao |
Merck |
2 |
| #21 |
Shaoqing Chen |
Hoffmann-La Roche |
2 |
| #21 |
Brian M. Weiss |
ExxonMobil |
2 |
| #21 |
Venkat Kishore Ryakala |
Genzyme |
2 |
| #21 |
Hong Cheng |
ExxonMobil |
2 |
| #21 |
Renee Yura |
Ortho-Clinical Diagnostics |
2 |
| #21 |
Wangkan Lin |
Infineum International Limited |
2 |
| #21 |
Keith Andrew Redzinski |
Unknown |
2 |
| #21 |
Nagaraju Manchiraju |
Verizon |
2 |
| #21 |
James Galloway |
Omrix Biopharmaceuticals |
2 |
| #42 |
Yu Huang |
Futurewei Technologies |
1 |
| #42 |
Saijun Gong |
Merial |
1 |
| #42 |
Chris Lane |
Intel |
1 |
| #42 |
James DiNunzio |
University Of Texas System |
1 |
| #42 |
Michael L. Conrad, Jr. |
— |
1 |
| #42 |
Thomas Lee Craven |
Johnson & Johnson |
1 |
| #42 |
Jesus Molina |
Fujitsu Limited |
1 |
| #42 |
Mandar V. Dali |
Bristol-Myers Squibb |
1 |
| #42 |
James P. Walsh |
As Ip Holdco |
1 |